

Claims

1. The use of antagonists of placental growth factor for the manufacture of a medicament to treat disorders of bone resorption.
  - 5 2. The use according to claim 1 wherein said treatment of disorders of bone resorption is a suppression of bone resorption.
  3. The use of antagonists according to claims 1 and 2 wherein said antagonists are selected from the group consisting of antibodies binding on placental growth factor, peptides binding on placental growth factor, tetrameric peptides binding on placental growth factor or VEGFR-1, small molecules binding on placental growth factor or VEGFR-1, anti-sense nucleic acids against placental growth factor or VEGFR-1, interference RNA against placental growth factor or VEGFR-1 and ribozymes against placental growth factor or VEGFR-1.
  - 0 4. The use according to claims 1, 2 and 3 wherein said bone resorption is osteoporosis.
  - 5 5. A method of inhibiting a condition of enhanced bone resorption in a patient in need of such treatment, said treatment comprising administering a VEGFR-1/PIGF signalling pathway modulator in amounts effective to suppress bone resorption.
  6. The method of claim 5, to treat osteoporosis in a patient in need of such treatment.
  7. The method of claim 5 or 6, wherein the modulator is a PIGF inhibitor.
  - 0 8. The method of claim 5 or 6, wherein the modulator is a VEGFR-1 inhibitor.
-